An international research team has reported a blood test that identified early breast cancer with 95% accuracy in the tests described and could predict post-treatment recurrence risk with 81% accuracy. The result, reported by Digi24 from a Weizmann Institute statement and described as published in Nature, is a notable research development. On the information available, however, it is not a test ready to replace current screening or determine treatment on its own.
The method analyses chemical markers in blood linked to tiny traces of cancer cells. The report says the researchers also found a small group of particularly aggressive cells inside tumours that can appear relatively harmless. Those cells may survive treatment and contribute to recurrence. That is why the work matters: earlier identification of a higher-risk group could eventually help doctors tailor follow-up more closely.
The 95% and 81% figures must be read as reported results from the study's tests, rather than as a promise of immediate clinical use. The supplied material does not give the sample size or participant profile, a direct comparison with existing screening methods, external validation, regulatory status, cost, or availability in routine care in Romania. It therefore cannot establish that the blood test is ready for population screening or for changing clinical decisions.
The researchers' view that the technology could help identify higher-risk patients and select appropriate treatment is a meaningful aim. But the public value of this announcement lies chiefly in a promising route for detection and monitoring, not in a currently available alternative to established care. Screening and treatment decisions should continue to be made with a clinical team using the methods available for the individual patient.
The relevant next step is examination of the original Nature paper for its participant data, test design, clinical comparisons and the validation required before routine use.
Sources
- Digi24 · Source date: 2026-11-14
Independent editorial content. WUA is not affiliated with any political party. 2026-11-14